menu
    • menu
    [{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Biotheus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"TILT-123","moa":"TNF-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TILT Biotherapeutics \/ Biotheus","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ Biotheus"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Lifeline Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Large molecule","year":"2020","type":"Financing","leadProduct":"TILT-123","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"TILT Biotherapeutics \/ Lifeline Ventures","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ Lifeline Ventures"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"TNF alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TILT Biotherapeutics \/ TILT Biotherapeutics","highestDevelopmentStatusID":"5","companyTruncated":"TILT Biotherapeutics \/ TILT Biotherapeutics"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"TILT-123","moa":"TNF-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TILT Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"TNF-alpha","graph1":"Oncology","graph2":"IND Enabling","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"TILT Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"TILT Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"TILT-123","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TILT Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Finland\u2019s Lifeline Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"Avelumab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"TILT Biotherapeutics \/ Finland\u2019s Lifeline Ventures","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ Finland\u2019s Lifeline Ventures"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FINLAND","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Avelumab","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"TILT Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"Igrelimogene Litadenorepvec","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TILT Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TILT Biotherapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"TILT Biotherapeutics \/ U.S. Department of Defense"}]

    Find Clinical Drug Pipeline Developments & Deals by TILT Biotherapeutics

    Menu

    TILT Biotherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TILT Biotherapeutics

                            Finland arrow
                            Antibody Engineering
                            Not Confirmed

                            TILT Biotherapeutics

                            Finland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Igrelimogene Litadenorepvec,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : U.S. Department of Defense

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            TILT Awarded $2 Million Grant from U.S. Department of Defense for Ovarian Cancer Research

                            Details : The funding aims to support the clinical development of TILT-123 (igrelimogene litadenorepvec) in combination with pembrolizumab for treating platinum-resistant/refractory ovarian cancer patients.

                            Brand Name : TILT-123

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 14, 2024

                            Lead Product(s) : Igrelimogene Litadenorepvec,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : U.S. Department of Defense

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TILT Biotherapeutics

                            Finland arrow
                            Antibody Engineering
                            Not Confirmed

                            TILT Biotherapeutics

                            Finland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Igrelimogene Litadenorepvec,Avelumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TILT Biotherapeutics Announces First Patient Dosed in Phase I Solid Tumors Trial Assessing Oncolytic Adenoviru...

                            Details : TILT-123 (igrelimogene litadenorepvec) is a 5/3 chimeric serotype adenovirus armed with two human cytokines, which is being evaluated in combination with avelumab for squamous cell carcinoma of head and neck, and melanoma.

                            Brand Name : TILT-123

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 15, 2023

                            Lead Product(s) : Igrelimogene Litadenorepvec,Avelumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TILT Biotherapeutics

                            Finland arrow
                            Antibody Engineering
                            Not Confirmed

                            TILT Biotherapeutics

                            Finland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TILT-123,Avelumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Finland’s Lifeline Ventures

                            Deal Size : $23.8 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Im...

                            Details : The funding will be used to advance to Phase II the company’s combination trials of TILT-123 which use oncolytic immunotherapies synergistically with checkpoint inhibitors.

                            Brand Name : TILT-123

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 07, 2023

                            Lead Product(s) : TILT-123,Avelumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Finland’s Lifeline Ventures

                            Deal Size : $23.8 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            TILT Biotherapeutics

                            Finland arrow
                            Antibody Engineering
                            Not Confirmed

                            TILT Biotherapeutics

                            Finland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TILT-123

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TILT Biotherapeutics Announces Positive Update on its Phase 1 Immunotherapy Clinical Trials in Cancer

                            Details : TILT-123 is a human 5/3 chimeric adenovirus that has been engineered for targeting, safety and potency, is an oncolytic adenovirus coding for Tumor Necrosis Factor Alpha (TNF alpha) and Interleukin 2 (IL-2), designed to stimulate T cells to better fight ...

                            Brand Name : TILT-123

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 31, 2022

                            Lead Product(s) : TILT-123

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            TILT Biotherapeutics

                            Finland arrow
                            Antibody Engineering
                            Not Confirmed

                            TILT Biotherapeutics

                            Finland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TILT-123,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TILT Biotherapeutics Submits IND for Phase I Trial of Immunotherapeutic TILT-123 in Ovarian Cancer

                            Details : The trial’s objective is to evaluate the safety and efficacy of TILT-123 in combination with pembrolizumab and is designed to also deliver insights about the mechanism of action of TILT-123 in humans.

                            Brand Name : TILT-123

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 14, 2021

                            Lead Product(s) : TILT-123,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            TILT Biotherapeutics

                            Finland arrow
                            Antibody Engineering
                            Not Confirmed

                            TILT Biotherapeutics

                            Finland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TILT-123

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TILT Biotherapeutics, Docrates Cancer Center and Helsinki University Hospital Open Cancer Immunotherapy Clinic...

                            Details : TILT Biotherapeutics has dosed its first patients and progressed to the second dose level in a monotherapy phase 1 clinical trial of TILT-123, a dual cytokine armed oncolytic adenovirus.

                            Brand Name : TILT-123

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 05, 2021

                            Lead Product(s) : TILT-123

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            TILT Biotherapeutics

                            Finland arrow
                            Antibody Engineering
                            Not Confirmed

                            TILT Biotherapeutics

                            Finland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TILT-123,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            TILT Biotherapeutics and MSD to Collaborate on Clinical Trial of TILT-123 in Combination with Keytruda for Ova...

                            Details : The trial’s objective is to evaluate the safety and efficacy of TILT-123 in combination with pembrolizumab and is designed to also deliver insights about the mechanism of action of TILT-123 in humans.

                            Brand Name : TILT-123

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 14, 2021

                            Lead Product(s) : TILT-123,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            TILT Biotherapeutics

                            Finland arrow
                            Antibody Engineering
                            Not Confirmed

                            TILT Biotherapeutics

                            Finland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TILT-123,Tumor infiltrating lymphocytes

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Lifeline Ventures

                            Deal Size : $6.9 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            TILT Biotherapeutics Secures Over EUR 6 million to Advance Cancer Immunotherapies Into Clinic

                            Details : Funds will be used to advance TILT's proprietary, best-in-class cytokine armed oncolytic adenovirus, TILT-123, into Phase 1 clinical trials in Europe and the United States, and to prepare for Phase 2 trials.

                            Brand Name : TILT-123

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 16, 2020

                            Lead Product(s) : TILT-123,Tumor infiltrating lymphocytes

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Lifeline Ventures

                            Deal Size : $6.9 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            TILT Biotherapeutics

                            Finland arrow
                            Antibody Engineering
                            Not Confirmed

                            TILT Biotherapeutics

                            Finland arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TILT-123

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Biotheus

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            TILT Biotherapeutics Signs a Licensing Deal with Biotheus, Inc for Cancer Therapy with Oncolytic Virus TILT-12...

                            Details : Under the agreement TILT has granted Biotheus rights for development and commercialization of TILT’s proprietary oncolytic virus TILT-123 in Greater China.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 27, 2020

                            Lead Product(s) : TILT-123

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Biotheus

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth